Manufacturing in Ireland

Astellas Pharma have two manufacturing plants in Ireland. One in Mulhuddart, Dublin 15 and one in Killorglin Co Kerry.


Astellas Dublin, Ireland

Astellas Ireland Co; Limited
Damastown Road
Damastown Industrial Park
Mulhuddart
Dublin 15

Astellas is a pharmaceutical company that is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.

Keeping our focus on addressing unmet medical needs and conducting our business with openness, integrity and a collaborative approach enables us to improve the health of people around the world.

Astellas Ireland Co., Ltd Dublin Plant is part of the Astellas pharmaceutical group, a trans-global pharmaceutical company resulting from the merger of Yamanouchi and Fujisawa. Our parent, Astellas Pharma Inc., is the second largest pharmaceutical company in Japan.

The facility in Mulhuddart was established (originally as Yamanouchi) in 1986 as a manufacturing plant for Active Pharmaceutical Ingredients for medicinal products, with production operations commencing in July 1988.

Located in west Dublin, the plant is conveniently located close to Dublin Airport, the City Centre and some of the best Universities in Ireland.

Astellas currently uses approximately one third of its 50-acre Dublin site for production and related activities with the remainder of the land being available for future development and site expansion.

Today the bulk active pharmaceutical ingredients manufactured on our site include Mirabegron, Solifenacin and Tamsulosin used in the treatment of overactive bladder and prostate gland disorder. These products are shipped to our customers for final, formulation, packaging and distribution to a global market.

At the Dublin plant, we live the Astellas Way, and our values of patient focus, ownership, results, openness and integrity are the foundation of our culture, guiding all of our actions.


Astellas Kerry, Ireland

Astellas Ireland Co; Limited
Killorglin
Co Kerry


Astellas Ireland’s Kerry Plant manufactures a range of treatments, including the immunosuppressant Prograf® which is supplied globally from Killorglin.The Kerry Plant was established in Killorglin in 1990 and currently employs 250 permanent staff.

As part of Astellas corporate environmental initiative program of utilising renewable energy and to implement measures designed to protect the environment, a 800 KW wind turbine power generation station and a 1.8 MW wood chip boiler system have been installed in its Kerry Plant.

The combined construction of the station and the boiler system is expected to reduce the plant’s carbon dioxide emissions by over 3,000 tonnes per year.

The formal planning approval of the construction of the wind turbine power generation station was received in November 2010 and was completed successfully in January 2012. The wind turbine has a tower height of 73 metres, a rotor blade diameter of 53 metres and an overall base to tip height of 99 metres. The station will generate approximately 20% of the plants electrical requirements and reduce the plant’s carbon dioxide and nitrogen oxide emissions by over 1,000 and 4 tonnes per year, respectively.

The wood chip boiler was installed successfully in April 2012.

* Famotidine is not marketed by APCL

APCL18001IRE